122 -4 (78) 2025 - Mustafaeva Sh.A. - NSAIDS - NEPHROPATHY

NSAIDS - NEPHROPATHY

Mustafaeva Sh.A. - Bukhara State Medical Institute named after Abu Ali ibn Sina

Resume

Kidney damage is a very common phenomenon in patients with rheumatological and may develop either due to the disease itself or secondary to the medications used in treatment. The prevalence of kidney damage and its severity depend on the underlying disease, as well as the severity of the therapy. For most rheumatological diseases, kidney damage is a bad prognosis and requires aggressive immunosuppressive treatment. On the other hand, it is practically impossible to group NSAIDs according to their greater or lesser adverse effects on the kidneys - comparative scientific studies are very rare. Therefore, it is important to diagnose and treat them at an early stage. However, it can be argued that almost all NSAIDs (including selective COG-2 inhibitors) have adverse effects on the kidneys.

Keywords: rheumatoid arthritis, nephropathy, chronic kidney diseases, nonsteroidal anti-inflammatory drugs.

First page

700

Last page

706

For citation:Mustafaeva Sh.A. - NSAIDS - NEPHROPATHY//New Day in Medicine 4(78)2025 700-706 https://newdayworldmedicine.com/en/new_day_medicine/4-78-2025

List of References

  1. Agodoa LY, Francis ME, Eggers PW. Association of analgesic use with prevalence of albuminuria and reduced GFR in US adults. Am J Kidney Dis 2008; 51: 573–83.
  2. Akhmadovna M. S. Reasons for the Development of Morphostructural Changes in Kidney Cells in Patients with Rheumatoid Arthritis //Vital Annex: International Journal of Novel Research in Advanced Sciences. – 2022. – Т. 1. – №. 5. – С. 396-401.
  3. Chang Yu-Kang et al. Increased Risk of End-Stage Renal Disease (ESRD) Requiring Chronic Dialysis is Associated With Use of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs). Medicine (Baltimore) 2015; 94 (38): e1362. DOI: 10.1097/MD.0000000000001362.
  4. Chang Yu-Kang et al. Increased Risk of End-Stage Renal Disease (ESRD) Requiring Chronic Dialysis is Associated With Use of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs).Medicine (Baltimore) 2015; 94 (38): e1362. DOI: 10.1097/MD.0000000000001362.
  5. Cheng Y., Austin S.C., Rocca B., et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science. 2002; 296: 539–541.
  6. Crofford LJ. COX-1 and COX-2 tissue expression: implications and redictions. J Rheumatol Suppl 1997; 49: 15–9.
  7. Davies N.M., Good R.L., Roupe K.A. et al. Cyclooxygenase-3: axiom, dogma, anomaly, enigma or splice error? – not as easy as 1,2,3. J. Pharm. Pharmaceut Sci. 2004; 7(2): 217–226.
  8. Dreischulte T, Morales DR, Bell S, Guthrie B. Combined use of nonsteroidal anti-inflammatory drugs with diuretics and/or renin-angiotensin system inhibitors in the community increases the risk of acute kidney injury. Kidney Int 2015; 88 (2): 396–403. DOI:10.1038/ki.2015.101. Epub 2015 Apr 15.
  9. Dyadyk A.I., Kugler T.E. Side effects of non-steroidal anti-inflammatory drugs. Consilium Medicum. 2017; 19 (12): 94–99. DOI: 10.26442/2075-1753_19.12.94-99.
  10. Egan K.M., Lawson J.A., Fries S. et al. COX-2 derived prostacycline confers atheroprotection on female mice. Science. 2004; 306: 1954–1957.FANLARI ILMIY JURNALI. – 2022. – Т. 1. – №. 4. – С. 22-27.
  11. Fernández-Nebro A, Tomero E, Ortiz-Santamaría V, et al. Treatment of rheumatic inflamma-tory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists // Am J Med. 2005;118(5):52-556.doi:10.1016/j.am-jmed.2005.01.028.
  12. Gambaro G, Perazella MA. Adverse renal effects of anti-inflammatory agents: evaluation of selective and nonselective cyclooxygenase inhibitors. J Intern Med 2003; 253 (6): 643–52.
  13. Gottenberg JE, Merle-Vincent F, Bentaberry F, et al. Anti-tumor necrosis factor alpha therapy in fif-teen patients with AA amyloidosis secondary to inflam-matory arthritides: a followup report of tolerability and efficacy // Arthritis Rheum. 2003;48(7):2019-2024. doi:10.1002/art.11163.
  14. Hцrl W et al. Nonsteroidal Anti-Inflammatory Drugs and the Kidney. Pharmaceuticals (Basel) 2010; 3 (7): 2291–321.
  15. Ifuku M., Miyake K., Watanebe M. et al. Various roles of Th cytokine mRNA expression in different formsof glomerulonephritis. Amer. J. Nephrol. 2013; 38 (2):115–123. DOI: 10.1159/000353102.
  16. Imig J.D., Ryan M.J. Immune and inflammatory role in renal disease. Compr. Physiol. 2013; 3 (2): 957–976.DOI: 10.1002/cphy.c120028.
  17. Ingrasciotta Y, Sultana J, Giorgianni F et al. Association of Individual Non-Steroidal Anti- Inflammatory Drugs and Chronic Kidney Disease: A Population-Based Case Control Study. PLoS ONE 2015; 10 (4): e0122899. DOI:10.1371/journal.pone. 0122899.
  18. Jonson AG. NSAIDs and increased blood pressure. What is clinical significance? Drug Safety 1997; 17: 277–89.
  19. Kholmurodovich U. F. Damage to the digestive system when using non-steroidal anti-inflammatory drugs //European journal of modern medicine and practice. – 2022. – Т. 2. – №. 1. – С. 6-16.
  20. Kochi M, Kohagura K, Shiohira Y, et al. In-flammation as a Risk of Developing Chronic Kidney Disease in Rheumatoid Arthritis // PLOS ONE. 2016. doi:10.1371/journal.pone.016022.

    file

    download